Is HBPCF or DIVO a better dividend investment in 2026?

HBPCF currently yields 115.61% with a 5% 5-year dividend growth rate. DIVO yields 6.49% with 5% growth. The better choice depends on your goal: HBPCF offers higher current income.

What is the dividend yield difference between HBPCF and DIVO?

HBPCF has a forward dividend yield of 115.61% ($2.00/share annually). DIVO yields 6.49% ($2.91/share annually). The yield gap is 109.12 percentage points.

Home › Compare › HBPCF vs DIVO

HBPCF vs DIVO: Dividend Comparison 2026

HBPCF yields 115.61% · DIVO yields 6.49%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 HBPCF wins by $7.20M in total portfolio value

INVESTMENT

TIME HORIZON10 years

HBPCF

● Live price

115.61%

Share price

$1.73

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$7.23M

Annual income

$2,676,132.53

Full HBPCF calculator →

DIVO

● Live price

6.49%

Share price

$44.85

Annual div

$2.91

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.7K

Annual income

$981.68

Full DIVO calculator →

Portfolio growth — HBPCF vs DIVO

📍 HBPCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	HBPCF	DIVO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, HBPCF + DIVO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

HBPCF pays

DIVO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HBPCF

Annual income on $10K today (after 15% tax)

$9,826.59/yr

After 10yr DRIP, annual income (after tax)

$2,274,712.65/yr

DIVO

Annual income on $10K today (after 15% tax)

$552.00/yr

After 10yr DRIP, annual income (after tax)

$834.43/yr

At 15% tax rate, HBPCF beats the other by $2,273,878.22/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HBPCF + DIVO for your $10,000?

HBPCF: 50%DIVO: 50%

100% DIVO50/50100% HBPCF

Portfolio after 10yr

$3.63M

Annual income

$1,338,557.10/yr

Blended yield

36.87%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HBPCF buys

DIVO buys

No recent congressional trades found for HBPCF or DIVO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricHBPCFDIVO

Forward yield	115.61% ✓	6.49%
Annual dividend / share	$2.00	$2.91 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$7.23M	$30.7K ✓
Annual income after 10y	$2,676,132.53 ✓	$981.68
Total dividends collected	$6.55M	$8.2K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: HBPCF vs DIVO ($10,000, DRIP)

Year	HBPCF Portfolio	HBPCF Income/yr	DIVO Portfolio	DIVO Income/yr	Gap
1← crossover	$22,261	$11,560.69	$11,349	$649.42	+$10.9K → HBPCF
2	$47,870	$24,051.31	$12,833	$688.83	+$35.0K → HBPCF
3	$99,558	$48,337.27	$14,459	$727.90	+$85.1K → HBPCF
4	$200,481	$93,953.00	$16,238	$766.49	+$184.2K → HBPCF
5	$391,330	$176,815.76	$18,179	$804.47	+$373.2K → HBPCF
6	$741,281	$322,558.19	$20,293	$841.71	+$721.0K → HBPCF
7	$1,364,208	$571,036.96	$22,591	$878.14	+$1.34M → HBPCF
8	$2,441,853	$982,150.40	$25,087	$913.65	+$2.42M → HBPCF
9	$4,255,766	$1,642,983.32	$27,791	$948.18	+$4.23M → HBPCF
10	$7,229,802	$2,676,132.53	$30,718	$981.68	+$7.20M → HBPCF

HBPCF vs DIVO: Complete Analysis 2026

HBPCF — Stock

Helix BioPharma Corp. operates as an immune-oncology company in Canada. The company is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

Full HBPCF Calculator →

DIVO — ETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →

📬

Get this HBPCF vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HBPCF vs SCHD HBPCF vs JEPI HBPCF vs O HBPCF vs KO HBPCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.